Back
Compare AU
Compare DRUG vs. MKAX
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Betashares Global Healthcare Currency Hedged ETF (DRUG) and the Montaka Global Extension Fund - Complex ETF (MKAX). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | MKAX | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 74 | 1 |
Median incremental investment | $745.07 | $4,990.50 |
Median investment frequency | Monthly | Fortnightly |
Median total investment | $1,592.71 | $4,558.40 |
Average age group | > 35 | 26 - 35 |
Key Summary
DRUG | MKAX | |
|---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | MKAX.AX was created on 2020-06-24 by Montaka. The fund's investment portfolio concentrates primarily on long/short alternatives. The Fund aims to provide Unitholders with long term capital growth, with a focus on managing downside risk. |
Top 3 holdings | AUD - AUSTRALIA DOLLAR (0 %) BRL - BRAZILIAN REAL (0 %) CHF - SWISS FRANC (0 %) | KKR & Co Inc Ordinary Shares (16.20 %) Amazon.com Inc (15.25 %) Blackstone Inc (14.34 %) |
Top 3 industries | Other (75.91 %) Communication Services (33.53 %) Health Care (23.80 %) | Financials (30.27 %) Information Technology (27.44 %) Consumer Discretionary (21.33 %) |
Top 3 countries | United States (69.91 %) Switzerland (10.93 %) United Kingdom of Great Britain and Northern Ireland (7.38 %) | United States (88.72 %) China (4.98 %) Australia (2.24 %) |
Management fee | 0.57 % | 1.25 % |
Key Summary
DRUG | MKAX | |
|---|---|---|
Issuer | BetaShares | Montaka |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | |
Asset class | ETF | ETF |
Management fee | 0.57 % | 1.25 % |
Price | $8.54 | $2.97 |
Size | $176.152 million | N/A |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 1.92 % | 5.95 % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 23/06/2020 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | MKAX | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 74 | 1 |
Median incremental investment | $745.07 | $4,990.50 |
Median investment frequency | Monthly | Fortnightly |
Median total investment | $1,592.71 | $4,558.40 |
Average age group | > 35 | 26 - 35 |
Pros and Cons
DRUG | MKAX | |
|---|---|---|
Pros |
|
|
Cons |
|
|
DRUG | MKAX |
|---|---|
Lower exposure to AU market | Higher exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |